Helix BioPharma said that the product revenue contributed to the increase in revenue in fiscal 2010 when compared to fiscal 2009 and was offset slightly by a decrease in license fees and royalties.
Product revenue in fiscal 2010 totaled $3.92m and represents an increase of 21% when compared to product revenue in fiscal 2009 of $3.24m.
Helix BioPharma posted a net loss of $14.47m, or $0.24 loss per diluted share for the full year ended 2010, compared to $14.1m, or $0.27 loss per diluted share, for the year 2009.